Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on Barrigel and BioProtect

The Phase 3 trials for the Barrigel and BioProtect rectal spacers demonstrated a dosimetric advantage and reduced rectal toxicity similar to SpaceOAR, but data on long-term toxicity and patient-reported outcomes is still needed to fully evaluate the newer spacers.

EP: 1.The Role of Rectal Spacers in Patients Undergoing Radiation Therapy for Prostate Cancer

EP: 2.Common Adverse Effects in Patients With Prostate Cancer Undergoing Radiation Therapy

EP: 3.Available Rectal Spacer Options for Patients With Prostate Cancer Undergoing Radiation Therapy

EP: 4.Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on SpaceOAR and SpaceOAR Vue

Now Viewing

EP: 5.Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on Barrigel and BioProtect

EP: 6.Impact of Rectal Spacers on Sexual Quality-of-Life After Radiotherapy in Patients With Prostate Cancer

EP: 7.Recommendations for the Use of Rectal Spacers in Clinical Practice for Patients With Prostate Cancer

EP: 8.Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation Therapy

Related Videos

Related Content

Advertisement

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

Related Content

Advertisement

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.